Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study-Reference-Cited by-同舟云学术

Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study

Published:2023-07-14 Issue:10 Volume:58 Page:1043-1054
ISSN:0944-1174
Container-title:Journal of Gastroenterology
language:en
Short-container-title:J Gastroenterol

Author:

Li Le,Wu Pei-Sheng,Liang Xiu-Mei,Chen Kang,Zhang Guan-Lan,Su Qi-Bin,Huo Rong-Rui,Xie Rong-Wei,Huang Shan,Ma Liang,Zhong Jian-Hong^ORCID

Funder

Specific Research Project of Guangxi for Research Bases and Talents

National Natural Science Foundation of China

Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor (Guangxi Medical University), Ministry of Education

Self-raised Scientific Research Fund of the Ministry of Health of Guangxi Province

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

https://link.springer.com/content/pdf/10.1007/s00535-023-02018-2.pdf

Reference42 articles.

1. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681–93.

2. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.

3. Kudo M, Kawamura Y, Hasegawa K, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer. 2021;10:181–223.

4. Zhou J, Sun H, Wang Z, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 Edition). Liver Cancer. 2020;9:682–720.

5. Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol. 2022;2022(28):583–705.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic treatment in unresectable hepatocellular carcinoma: The most concerns;iLIVER;2024-09

2. Postoperative lenvatinib + PD-1 blockade reduces early tumor recurrence in hepatocellular carcinoma with microvascular invasion (Barcelona Clinic Liver Cancer stage 0 or A): a propensity score matching analysis;Journal of Gastrointestinal Surgery;2024-07

3. Recent advances in surgical management strategies for hepatocellular carcinoma;hLife;2024-06

4. Can adjuvant immune checkpoint inhibitors improve the long-term outcomes of hepatocellular carcinoma with high-risk recurrent factors after liver resection? A meta-analysis and systematic review;Frontiers in Oncology;2024-05-24

5. Adjuvant Therapy for Hepatocellular Carcinoma After Curative Treatment: Several Unanswered Questions;Journal of Clinical and Translational Hepatology;2024-04-24